Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

NCT00100256 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Small Cell
Neoplasm Recurrence, Local

Interventions

DRUG: Rhenium (Re 188 P2045, BAY86-5284)

Sponsor

Andarix Pharmaceuticals